Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Athenex, Inc.ATNX · Entity 113753 | See Remarks | June 13, 2017 | August 21, 2018 |
| Moleculin Biotech, Inc.MBRX · Entity 7886 | Director | November 12, 2025 | November 14, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Athenex, Inc.
Report date June 13, 2017 · Filed August 21, 2018 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.00 · Expires 2027-06-13 | Direct | 18,000 |
Reported balance
After 2017-06-13 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2017-06-13 · Grant · Acquired 18,000 · Balance 18,000 F1: This option was previously reported by Mr. Cannon. This amendment is being filed to correct the transaction date, exercise date, and expiration date. F2: This option vests in four equal annual installments beginning on June 13, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was previously reported by Mr. Cannon. This amendment is being filed to correct the transaction date, exercise date, and expiration date.
F2: This option vests in four equal annual installments beginning on June 13, 2018.
Moleculin Biotech, Inc.
Report date November 12, 2025 · Filed November 14, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.49 · Expires 2035-11-12 | Direct | 165,336 |
Reported balance
After 2025-11-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-11-12 · Grant · Acquired 150,000 · Balance 165,336 F2: The options were issued in connection with the reporting person's Board of Director service to the Company. F1: The options set forth in this table vest on November 12, 2026, subject to the grantee's continued service on the Company's Board of Directors on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options set forth in this table vest on November 12, 2026, subject to the grantee's continued service on the Company's Board of Directors on each vesting date.
F2: The options were issued in connection with the reporting person's Board of Director service to the Company.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 12, 2025 Filed Nov 14, 2025 21:06 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | GrantStock Options (right to buy) · Derivative | 150,000 | Not disclosed Strike: $0.49 | Not disclosed |
DisclosureSEC source: 0001437749-25-035174 · rdgdoc.xml · derivative · entry 1 CANNON MICHAEL D · CIK 0001203602 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,336 Underlying: Common Stock · 150,000 shares Expires 2035-11-12 F2 · price: The options were issued in connection with the reporting person's Board of Director service to the Company. F1 · derivative.exercise_date: The options set forth in this table vest on November 12, 2026, subject to the grantee's continued service on the Company's Board of Directors on each vesting date. Read SEC document |
| November 04, 2024 Filed Nov 7, 2024 01:03 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | GrantStock option (right to buy) · Derivative | 10,000 | Not disclosed Strike: $2.45 | Not disclosed |
DisclosureSEC source: 0001437749-24-033706 · rdgdoc.xml · derivative · entry 1 CANNON MICHAEL D · CIK 0001203602 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,336 Underlying: Common Stock · 10,000 shares Expires 2034-11-04 F2 · price: The options were issued in connection with the reporting person's Board of Director service to the Company. F1 · derivative.exercise_date: The options set forth in this table vest through April 2025, subject to the grantee's continued service on the Company's Board of Directors on each vesting date. Read SEC document |
| May 25, 2023 Filed May 26, 2023 21:15 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | GrantStock option (right to buy) · Derivative | 15,000 | Not disclosed Strike: $0.62 | Not disclosed |
DisclosureSEC source: 0001437749-23-016001 · rdgdoc.xml · derivative · entry 1 CANNON MICHAEL D · CIK 0001203602 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,001 Underlying: Common Stock · 15,000 shares Expires 2033-05-25 F2 · price: The options were issued in connection with the reporting person's Board of Director service to the Company. F1 · derivative.exercise_date: The options set forth in this table vest on the earlier of one year from the date of the Company's 2023 annual meeting of stockholders or on the next annual meeting of stockholders, subject to the grantee's continued service on the Company's Board of Directors on such vesting date. Read SEC document |
| June 20, 2022 Filed Jun 22, 2022 23:03 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | GrantStock option (right to buy) · Derivative | 15,000 | Not disclosed Strike: $1.49 | Not disclosed |
DisclosureSEC source: 0001437749-22-015660 · rdgdoc.xml · derivative · entry 2 CANNON MICHAEL D · CIK 0001203602 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,001 Underlying: Common Stock · 15,000 shares Expires 2032-06-20 F3 · price: The options were issued in connection with the reporting person's Board of Director service to the Company. F2 · derivative.exercise_date: The options set forth in this table vest on the earlier of one year from the date of the Company's 2022 annual meeting of stockholders or on the date of the next annual meeting of stockholders, subject the grantee's continued service on the Company's Board of Directors on each vesting date. Read SEC document |
| June 20, 2022 Filed Jun 22, 2022 23:03 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | GrantStock option (right to buy) · Derivative | 23,333 | Not disclosed Strike: $1.49 | Not disclosed |
DisclosureSEC source: 0001437749-22-015660 · rdgdoc.xml · derivative · entry 1 CANNON MICHAEL D · CIK 0001203602 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,001 Underlying: Common Stock · 23,333 shares Expires 2032-06-20 F3 · price: The options were issued in connection with the reporting person's Board of Director service to the Company. F1 · derivative.exercise_date: The options set forth in this table vest in three equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service on the Company's Board of Directors on each vesting date. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 20:26 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | GrantStock option (right to buy) · Derivative | 10,000 | Not disclosed Strike: $3.95 | Not disclosed |
DisclosureSEC source: 0001437749-21-014429 · rdgdoc.xml · derivative · entry 1 CANNON MICHAEL D · CIK 0001203602 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,668 Underlying: Common Stock · 10,000 shares Expires 2031-06-07 F2 · price: The options were issued in connection with the reporting person's Board of Director service to the Company. F1 · derivative.exercise_date: The options set forth in this table vest in four quarterly installments, subject to the grantee's continued service on the Company's Board of Directors on each vesting date. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 20:34 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | GrantStock option (right to buy) · Derivative | 15,000 | Not disclosed Strike: $1.12 | Not disclosed |
DisclosureSEC source: 0001659617-20-000153 · wf-form4_159242604415421.xml · derivative · entry 1 CANNON MICHAEL D · CIK 0001203602 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 15,000 shares Expires 2030-06-15 F2 · price: (2) The options were issued in connection with the reporting person's Board of Director service to the Company. F1 · derivative.exercise_date: (1) The options set forth in this table vest in four quarterly installments, subject to the grantee's continued service on the Company's Board of Directors in each vesting date. Read SEC document |
| July 11, 2019 Filed Jul 15, 2019 20:25 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | GrantStock option (right to buy) · Derivative | 35,000 | Not disclosed Strike: $1.31 | Not disclosed |
DisclosureSEC source: 0001659617-19-000107 · wf-form4_156322231160782.xml · derivative · entry 1 CANNON MICHAEL D · CIK 0001203602 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 35,000 shares Expires 2029-07-11 F2 · price: (2) The options were issued in connection with the reporting person's Board of Director service to the Company. F1 · derivative.exercise_date: (1) The options set forth in this table vest in four quarterly installments, subject to the grantee's continued service on the Company's Board of Directors on each vesting date. Read SEC document |
| May 22, 2019 Filed May 24, 2019 21:00 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | GrantStock option (right to buy) · Derivative | 15,000 | Not disclosed Strike: $1.15 | Not disclosed |
DisclosureSEC source: 0001144204-19-028196 · tv522432_4.xml · derivative · entry 1 CANNON MICHAEL D · CIK 0001203602 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 15,000 shares Expires 2029-05-22 F2 · price: The options were issued in connection with the reporting person's Board of Director service to the Company. F1 · derivative.exercise_date: The options set forth in this table vest in four quarterly installments, subject to the grantee's continued service on the Company's Board of Directors on each vesting date. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 21:27 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | GrantStock option (right to buy) · Derivative | 35,000 | Not disclosed Strike: $1.82 | Not disclosed |
DisclosureSEC source: 0001144204-18-033610 · tv496094_4.xml · derivative · entry 1 CANNON MICHAEL D · CIK 0001203602 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 35,000 shares Expires 2028-06-06 F2 · price: The options were issued in connection with the reporting person's Board of Director service to the Company. F1 · derivative.exercise_date: The options set forth in this table vest in three equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service on the Company's Board of Directors on each vesting date. Read SEC document |
| July 24, 2017 Filed Jul 27, 2017 01:10 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | GrantOption to purchase common stock · Derivative | 15,000 | Not disclosed Strike: $1.87 | Not disclosed |
DisclosureSEC source: 0001144204-17-038499 · v471463_4.xml · derivative · entry 1 CANNON MICHAEL D · CIK 0001203602 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 15,000 shares Expires 2027-07-24 F2 · price: The options were issued in connection with the reporting person's Board of Director service to the Company. F1 · derivative.exercise_date: The options set forth in this table vest in three equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service on the Company's Board of Directors on each vesting date. Read SEC document |
| June 19, 2017 Filed Jun 21, 2017 15:12 UTC | Athenex, Inc. ATNX · Entity 113753 | GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $11.00 | $0.00 |
DisclosureSEC source: 0000905148-17-000609 · form4.xml · derivative · entry 1 CANNON MICHAEL D · CIK 0001203602 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2027-06-19 F1 · derivative.exercise_date: The option vests in four equal annual installments beginning on June 19, 2018. Read SEC document |
| June 14, 2017 Filed Apr 27, 2018 16:37 UTC Amendment | Athenex, Inc. ATNX · Entity 113753 | GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $11.00 | $0.00 |
DisclosureSEC source: 0001209191-18-026608 · doc4a.xml · derivative · entry 1 CANNON MICHAEL D · CIK 0001203602 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2027-06-14 F1 · derivative.exercise_date: The option vests in four equal annual installments beginning on June 14, 2018. Read SEC document |
| June 13, 2017 Filed Aug 21, 2018 17:59 UTC Amendment | Athenex, Inc. ATNX · Entity 113753 | GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $11.00 | $0.00 |
DisclosureSEC source: 0001209191-18-047816 · doc4a.xml · derivative · entry 1 CANNON MICHAEL D · CIK 0001203602 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2027-06-13 F1 · date: This option was previously reported by Mr. Cannon. This amendment is being filed to correct the transaction date, exercise date, and expiration date. F1 · derivative.exercise_date: This option was previously reported by Mr. Cannon. This amendment is being filed to correct the transaction date, exercise date, and expiration date. F2 · derivative.exercise_date: This option vests in four equal annual installments beginning on June 13, 2018. F1 · derivative.expiration_date: This option was previously reported by Mr. Cannon. This amendment is being filed to correct the transaction date, exercise date, and expiration date. Read SEC document |
| September 23, 2016 Filed Sep 28, 2016 00:58 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | GrantOption to purchase common stock · Derivative | 20,000 | Not disclosed Strike: $5.71 | Not disclosed |
DisclosureSEC source: 0001144204-16-125635 · v449474_4.xml · derivative · entry 1 CANNON MICHAEL D · CIK 0001203602 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2026-09-23 F2 · price: The options were issued in connection with the reporting person's Board of Director service to the Company. F1 · derivative.exercise_date: The options set forth in this table vest in three equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service on the Company's Board of Directors on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.